{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:21:49Z","timestamp":1790990509946,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":3139,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There is great interest in the development of Ab-inducing subunit vaccines targeting infections, including HIV, malaria, and Ebola. We previously reported that adenovirus vectored vaccines are potent in priming Ab responses, but uncertainty remains regarding the optimal approach for induction of humoral immune responses. In this study, using OVA as a model Ag, we assessed the magnitude of the primary and anamnestic Ag\u2013specific IgG responses of mice to four clinically relevant vaccine formulations: replication-deficient adenovirus; modified vaccinia Ankara (a poxvirus); protein with alum; and protein in the squalene oil-in-water adjuvant Addavax. We then used flow cytometric assays capable of measuring total and Ag-specific germinal center (GC) B cell and follicular Th cell responses to compare the induction of these responses by the different formulations. We report that adenovirus vectored vaccines induce Ag insert\u2013specific GC B cell and Ab responses of a magnitude comparable to those induced by a potent protein\/squalene oil-in-water formulation whereas\u2014despite a robust overall GC response\u2014the insert-specific GC B cell and Ab responses induced by modified vaccinia Ankara were extremely weak. Ag-specific follicular Th cell responses to adenovirus vectored vaccines exceeded those induced by other platforms at day 7 after immunization. We found little evidence that innate immune activation by adenovirus may act as an adjuvant in such a manner that the humoral response to a recombinant protein may be enhanced by coadministering with an adenovirus lacking a transgene of interest. Overall, these studies provide further support for the use of replication-deficient adenoviruses to induce humoral responses.<\/jats:p>","DOI":"10.4049\/jimmunol.1502472","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T06:52:18Z","timestamp":1468479138000},"page":"1242-1251","source":"Crossref","is-referenced-by-count":36,"title":["Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines"],"prefix":"10.1093","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3552-4747","authenticated-orcid":false,"given":"Chuan","family":"Wang","sequence":"first","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford , Oxford OX3 7DQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-0142","authenticated-orcid":false,"given":"Matthew","family":"Hart","sequence":"additional","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford , Oxford OX3 7DQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-6779","authenticated-orcid":false,"given":"Cecilia","family":"Chui","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford , Oxford OX3 7FZ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Ajuogu","sequence":"additional","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford , Oxford OX3 7DQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2287-9488","authenticated-orcid":false,"given":"Iona J","family":"Brian","sequence":"additional","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford , Oxford OX3 7DQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone C","family":"de Cassan","sequence":"additional","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford , Oxford OX3 7DQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3877-9780","authenticated-orcid":false,"given":"Persephone","family":"Borrow","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford , Oxford OX3 7FZ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-1357","authenticated-orcid":false,"given":"Simon J","family":"Draper","sequence":"additional","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford , Oxford OX3 7DQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-7562","authenticated-orcid":false,"given":"Alexander D","family":"Douglas","sequence":"additional","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford , Oxford OX3 7DQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,15]]},"reference":[{"key":"2025030617474121100_r1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"2025030617474121100_r2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.drudis.2009.02.009","article-title":"The path to a successful vaccine adjuvant\u2014\u2018the long and winding road.\u2019","volume":"14","author":"O\u2019Hagan","year":"2009","journal-title":"Drug Discov. Today"},{"key":"2025030617474121100_r3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"2025030617474121100_r4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nm.1850","article-title":"Effective induction of high-titer antibodies by viral vector vaccines","volume":"14","author":"Draper","year":"2008","journal-title":"Nat. Med."},{"key":"2025030617474121100_r5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/erv.13.11","article-title":"Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets","volume":"12","author":"de Cassan","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"2025030617474121100_r6","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2013.05.091","article-title":"Utilizing poxviral vectored vaccines for antibody induction-progress and prospects","volume":"31","author":"Draper","year":"2013","journal-title":"Vaccine"},{"key":"2025030617474121100_r7","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1016\/j.vaccine.2010.08.068","article-title":"Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1","volume":"28","author":"Douglas","year":"2010","journal-title":"Vaccine"},{"key":"2025030617474121100_r8","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.4049\/jimmunol.1101004","article-title":"The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus","volume":"187","author":"de Cassan","year":"2011","journal-title":"J. Immunol."},{"key":"2025030617474121100_r9","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.4049\/jimmunol.1001760","article-title":"Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines","volume":"185","author":"Draper","year":"2010","journal-title":"J. Immunol."},{"key":"2025030617474121100_r10","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol. Ther."},{"key":"2025030617474121100_r11","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/mt.2014.157","article-title":"Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial","volume":"22","author":"Hodgson","year":"2014","journal-title":"Mol. Ther."},{"key":"2025030617474121100_r12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/CVI.00418-07","article-title":"Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses","volume":"15","author":"Geiben-Lynn","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"2025030617474121100_r13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4049\/jimmunol.180.1.64","article-title":"Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation","volume":"180","author":"Cockburn","year":"2008","journal-title":"J. Immunol."},{"key":"2025030617474121100_r14","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J. Virol."},{"key":"2025030617474121100_r15","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.4049\/jimmunol.178.6.3505","article-title":"Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus","volume":"178","author":"Zhu","year":"2007","journal-title":"J. Immunol."},{"key":"2025030617474121100_r16","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.181.3.2134","article-title":"Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo","volume":"181","author":"Appledorn","year":"2008","journal-title":"J. Immunol."},{"key":"2025030617474121100_r17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"Rhee","year":"2011","journal-title":"J. Virol."},{"key":"2025030617474121100_r18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-065X.2012.01124.x","article-title":"Germinal center selection and the development of memory B and plasma cells","volume":"247","author":"Shlomchik","year":"2012","journal-title":"Immunol. Rev."},{"key":"2025030617474121100_r19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/ni.2019","article-title":"Germinal center B and follicular helper T cells: siblings, cousins or just good friends?","volume":"12","author":"Nutt","year":"2011","journal-title":"Nat. Immunol."},{"key":"2025030617474121100_r20","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.4049\/jimmunol.1502137","article-title":"Vaccine induction of lymph node-resident simian immunodeficiency virus Env-specific T follicular helper cells in Rhesus macaques","volume":"196","author":"Vargas-Inchaustegui","year":"2016","journal-title":"J. Immunol."},{"key":"2025030617474121100_r21","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"2025030617474121100_r22","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J. Immunol."},{"key":"2025030617474121100_r23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J. Clin. Invest."},{"key":"2025030617474121100_r24","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.vaccine.2007.06.019","article-title":"Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant","volume":"25","author":"Ophorst","year":"2007","journal-title":"Vaccine"},{"key":"2025030617474121100_r25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine - preliminary report","volume-title":"N. Engl. J. Med","author":"Ledgerwood","year":"2014"},{"key":"2025030617474121100_r26","doi-asserted-by":"crossref","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"2025030617474121100_r27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0950268800052535","article-title":"The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur","volume":"116","author":"Pastoret","year":"1996","journal-title":"Epidemiol. Infect."},{"key":"2025030617474121100_r28","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"Webster","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030617474121100_r29","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II randomized, double-blinded comparison of a single high dose (5\u00d710(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1\u00d710(8) TCID50) in healthy vaccinia-na\u00efve individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"2025030617474121100_r30","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective efficacy of recombinant modified vaccinia virus Ankara delivering middle east respiratory syndrome Coronavirus spike glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"J. Virol."},{"key":"2025030617474121100_r31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/JVI.74.2.923-933.2000","article-title":"Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine","volume":"74","author":"Ram\u00edrez","year":"2000","journal-title":"J. Virol."},{"key":"2025030617474121100_r32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fimmu.2015.00348","article-title":"Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax","volume":"6","author":"de Cassan","year":"2015","journal-title":"Front. Immunol."},{"key":"2025030617474121100_r33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","article-title":"Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses","volume":"10","author":"Moon","year":"2011","journal-title":"Nat. Mater."},{"key":"2025030617474121100_r34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/14760584.2.2.197","article-title":"MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile","volume":"2","author":"Podda","year":"2003","journal-title":"Expert Rev. Vaccines"},{"key":"2025030617474121100_r35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing \u03b1-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Gar\u00e7on","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"2025030617474121100_r36","doi-asserted-by":"crossref","first-page":"e20977","DOI":"10.1371\/journal.pone.0020977","article-title":"Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1","volume":"6","author":"Biswas","year":"2011","journal-title":"PLoS One"},{"key":"2025030617474121100_r37","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.4049\/jimmunol.1003783","article-title":"Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference","volume":"187","author":"Forbes","year":"2011","journal-title":"J. Immunol."},{"key":"2025030617474121100_r38","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1073\/pnas.94.12.6244","article-title":"Site-specific de-N-glycosylation of diglycosylated ovalbumin in hen oviduct by endogenous peptide: N-glycanase as a quality control system for newly synthesized proteins","volume":"94","author":"Suzuki","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030617474121100_r39","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/JVI.02568-07","article-title":"Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A","volume":"82","author":"Sridhar","year":"2008","journal-title":"J. Virol."},{"key":"2025030617474121100_r40","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/302490a0","article-title":"Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen","volume":"302","author":"Smith","year":"1983","journal-title":"Nature"},{"key":"2025030617474121100_r41"},{"key":"2025030617474121100_r42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","article-title":"A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys","volume":"17","author":"Douglas","year":"2015","journal-title":"Cell Host Microbe"},{"key":"2025030617474121100_r43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.vaccine.2007.10.064","article-title":"Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines","volume":"26","author":"Miura","year":"2008","journal-title":"Vaccine"},{"key":"2025030617474121100_r44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1084\/jem.20131821","article-title":"Adjuvant-specific regulation of long-term antibody responses by ZBTB20","volume":"211","author":"Wang","year":"2014","journal-title":"J. Exp. Med."},{"key":"2025030617474121100_r45","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.187.6.885","article-title":"In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection","volume":"187","author":"Takahashi","year":"1998","journal-title":"J. Exp. Med."},{"key":"2025030617474121100_r46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.274.5284.94","article-title":"Phenotypic analysis of antigen-specific T lymphocytes","volume":"274","author":"Altman","year":"1996","journal-title":"Science"},{"key":"2025030617474121100_r47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"2025030617474121100_r48","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1128\/JVI.00264-12","article-title":"Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation","volume":"86","author":"Guzman","year":"2012","journal-title":"J. Virol."},{"key":"2025030617474121100_r49","doi-asserted-by":"crossref","first-page":"263ra160","DOI":"10.1126\/scitranslmed.3009980","article-title":"Rational design of small molecules as vaccine adjuvants","volume":"6","author":"Wu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2025030617474121100_r50","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol. Ther."},{"key":"2025030617474121100_r51","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus ebola vaccine\u2014preliminary report","volume":"374","author":"Rampling","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/197\/4\/1242\/61657981\/1502472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/197\/4\/1242\/61657981\/1502472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:00:20Z","timestamp":1741287620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/197\/4\/1242\/7964379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1502472","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,8]]},"published":{"date-parts":[[2016,8]]}}}